The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma

Isabella Lurje, Zoltan Czigany, Sarah Eischet, Jan Bednarsch, Tom Florian Ulmer, Peter Isfort, Pavel Strnad, Christian Trautwein, Frank Tacke, Ulf Peter Neumann, Georg Lurje – 25 May 2022 – Cholangiocarcinoma (CCA) is a rare but highly aggressive malignancy of the biliary system. Although it is amenable to surgical resection in early disease, outcomes are frequently dismal. Here, we investigated the prevalence of body composition (BC) alterations and their prognostic role for surgical patients with intrahepatic (iCCA) and perihilar (pCCA) disease.

Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis

Claire Harrington, Swathi Krishnan, Cara L. Mack, Paolo Cravedi, David N. Assis, Josh Levitsky – 24 May 2022 – Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self‐tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First‐line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking.

Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy

Kazuhiro Murai, Takahiro Kodama, Hayato Hikita, Akiyoshi Shimoda, Makoto Fukuoka, Keisuke Fukutomi, Satoshi Shigeno, Yuto Shiode, Daisuke Motooka, Yuichiro Higuchi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Yuki Tahata, Yuki Makino, Ryoko Yamada, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara – 23 May 2022 – Current anti–hepatitis B virus (HBV) therapies have little effect on covalently closed circular DNA (cccDNA) and fail to eliminate HBV.

Hepatotoxicity

The goal of the AASLD Hepatotoxicity SIG is to promote and encourage research, education, and awareness regarding human hepatotoxicity. As such, individuals with any of the following interests and expertise are encouraged to partake in SIG activities.

Subscribe to